Back to News
Market Impact: 0.4
Xeris Biopharma Q3 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Xeris Biopharma raised its 2026 revenue guidance and 2030 outlook after third-quarter sales rose 44% year over year. Growth was driven by rapid sales growth of Recorlev, its Cushing syndrome treatment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
XERS0.80
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise